Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
---|---|
Information provided by: | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
ClinicalTrials.gov Identifier: | NCT00000440 |
This study is a double-blind, placebo-controlled outpatient trial to improve, through the addition of sertraline (Zoloft), the abstinence and relapse rates in alcohol- dependent individuals currently taking naltrexone (Revia).
Condition | Intervention | Phase |
---|---|---|
Alcoholism |
Drug: naltrexone (Revia) Drug: sertraline (Zoloft) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study |
Official Title: | Sertraline and Naltrexone for Alcohol Dependents |
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | NIAAAFAR11222 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000440 |
Health Authority: | United States: Federal Government |
Mental Disorders Naltrexone Alcoholism Substance-Related Disorders Sertraline |
Disorders of Environmental Origin Alcohol-Related Disorders Serotonin Ethanol |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Narcotic Antagonists Physiological Effects of Drugs Psychotropic Drugs Serotonin Uptake Inhibitors |
Pharmacologic Actions Serotonin Agents Sensory System Agents Therapeutic Uses Peripheral Nervous System Agents Central Nervous System Agents Antidepressive Agents |